NEO Neogenomics Inc stock chart & analysis
Conviction 49HealthcareScan · Fri, Nov 6, 2026Neogenomics Inc (NEO) closed at $16.84 (+2.12%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 48, RS Rating 95, -16.4% from its 52-week high, +43.2% year to date. Sector: Healthcare · Services-Testing Laboratories.
Financials as of Wed, Sep 30, 2026 · quarterly.
NEO technical analysis
Trend
NEO's moving averages are mixed — no clean uptrend or downtrend. It closed 4.5% below the 50-day ($17.64) and 30.7% above the 200-day ($12.88). ADX(14) at 16 points to a weak trend — more range than direction. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 48, in the bearish half of its range. MACD crossed above its signal line 8 sessions ago. Its RS Rating of 95 puts its weighted 12-month performance ahead of about 95% of the US market.
Volume and volatility
Volume on the latest session ran 1.1× its 20-day average. It trades about $31.5M a day on average. ATR(14) is $0.9218, 5.5% of price — its typical daily range. Bollinger Bands are in a squeeze (3 sessions) — volatility is compressed. Chaikin Money Flow (0.13) shows accumulation.
Key levels
The chart pattern's support is $15.74 and its resistance $20.10. The 52-week range is $7.07 to $20.15; price is 16.4% below the high and 138.4% above the low. The VWAP anchored at the 52-week high is $16.87, above price.
Performance
NEO returned -3.1% (1 week), +5.1% (1 month), +1.3% (3 months), +87.9% (6 months), +61.5% (1 year), +43.2% (year to date).
About Neogenomics Inc
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Services-Testing Laboratories · Listed 1996 · 2,500 employees
Recent news
- NeoGenomics to Participate in Upcoming Investor ConferencesYahoo Finance · Fri, Nov 6, 2026
- Did Narrower Quarterly Loss Just Shift NeoGenomics Stock Investment Narrative?Yahoo Finance · Thu, Nov 5, 2026
- Missed NeoGenomics' Rally? Here Is What Holders SawSimply Wall St · Thu, Nov 5, 2026
Congress activity
Disclosed STOCK Act trades in NEO · 2 recent
Insider activity
SEC Form 4 transactions in NEO · open-market 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Stone Warren Pres & Chief Operating Officer · Common Stock · 2026-10-01 | Exercise | 17.56K | — | 2026-10-01 | 2026-10-05 |
Stone Warren Pres & Chief Operating Officer · Common Stock · 2026-10-01 | Tax | 6.91K | — | 2026-10-01 | 2026-10-05 |
Stone Warren Pres & Chief Operating Officer · Restricted Stock Unit · 2026-10-01 | Exercise | 17.56K | — | 2026-10-01 | 2026-10-05 |
Stone Warren Pres & Chief Operating Officer · Common Stock · 2026-08-21 | Exercise | 28.11K | — | 2026-08-21 | 2026-08-25 |
Stone Warren Pres & Chief Operating Officer · Common Stock · 2026-08-21 | Tax | 11.06K | — | 2026-08-21 | 2026-08-25 |
Stone Warren Pres & Chief Operating Officer · Restricted Stock Unit · 2026-08-21 | Exercise | 28.11K | — | 2026-08-21 | 2026-08-25 |
Aunan Greg D Chief Accounting Officer · Common Stock · 2026-08-04 | Sell | 20K | $321K | 2026-08-04 | 2026-08-06 |
Starrett Carolyn S Director · Stock Option (Right to Buy) · 2026-06-23 | Grant | 9.78K | — | 2026-06-23 | 2026-06-25 |
Starrett Carolyn S Director · Restricted Stock Unit · 2026-06-23 | Grant | 14.13K | — | 2026-06-23 | 2026-06-25 |
TETRAULT LYNN A. Director · Stock Option (Right to Buy) · 2026-06-01 | Other | — | — | 2026-06-01 | 2026-06-03 |
SEC filings
EDGAR filings in NEO · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.